Table 2. Features of AAS User Subgroups.
| Group | Between-group Comparisons | ||||
|---|---|---|---|---|---|
| Nondependent AAS users (N = 42) | Dependent AAS users(N = 20) | Dependent vs. nondependent AAS users | |||
| Mean (SD) | Mean Difference (95% confidence interval)a | ||||
| Age at first AAS use, years | 21.8 (4.7) | 23.6 (6.1) | -0.2 (-3.5, 3.0) | ||
| Lifetime weeks of AAS use | 25.7 (26.9) | 302.7 (245.4) | 238*** (142, 334) | ||
| Maximum weekly AAS dose, mg testosterone equivalent | 712 (631) | 1920 (966) | 993*** (531, 1456) | ||
| N (%) | Odds Ratio (95% confidence interval)a | ||||
| Used other performance-enhancing drugs | 5 (12) | 16 (80) | 28.5*** (4.3, 187.1) | ||
| Used AAS for competitive sports | 4 (10) | 3 (15) | 0.9 (0.1, 8.6) | ||
| AAS-associated mood disorder: | |||||
| - mania or hypomania | 3 (7) | 5 (25) | 4.3 (0.6, 20.4) | ||
| - major depression | 1 (2) | 2 (10) | 9.3 (0.4, 213.0) | ||
a
Estimates adjusted for age, study site, and ethnicity (see text). * p < 0.05; ** p < 0.01; *** p < 0.001